Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that can result in severe muscle weakness and paralysis, loss of vision, respiratory failure and neuropathic pain.
{iframe}https://www.businesswire.com/news/home/20190906005062/en/Viela-Bio-Announces-Publication-Lancet-Pivotal-Study{/iframe}